• linkedin
  • Increase Font
  • Sharebar

    9 Newly Approved Novel Drugs

    It's been a busy year for the FDA.


    Plaque Psoriasis

    4. Siliq (brodalumab), Valeant Pharmaceuticals

    Indications: A human interleukin-17 receptor A (IL-17RA) antagonist used to manage moderate-to-severe plaque psoriasis. It is indicated for adultcandidates for systemic therapy or phototherapy who have failed to respond or who have stopped responding to other systemic therapies.

    Dosage: 210 mg by subcutaneous injection at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.

    Contraindications: Crohn’s disease

    Read the FDA statement here

    Read the full prescribing information here

    Previous ButtonNext Button



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available